A China-Based Cost-Effectiveness Analysis of Novel Oral Anticoagulants versus Warfarin in Patients with Left Ventricular Thrombosis

References

• Levine GN, McEvoy JW, Fang JC. et al. Management of patients at risk for and with left ventricular thrombus: a scientific statement from the American Heart Association. Circulation. 2022;146(15):e205–e223. doi:10.1161/CIR.0000000000001092
   PubMed Web of Science ®Google Scholar
• Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160–2236. doi:10.1161/STR.0000000000000024
   PubMed Web of Science ®Google Scholar
• Vallabhajosyula S, Kanwar S, Aung H, et al. Temporal trends and outcomes of left ventricular aneurysm after acute myocardial infarction. Am J Cardiol. 2020;133:32–38. doi:10.1016/j.amjcard.2020.07.043
   PubMed Web of Science ®Google Scholar
• O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):e362–425. doi:10.1161/CIR.0b013e3182742c84
   PubMed Web of Science ®Google Scholar
• Altiok E, Marx N. Oral Anticoagulation. Deutsches Arzteblatt Int. 2018;115(46):776–783. doi:10.3238/arztebl.2018.0776
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016;50(5):e1–e88. doi:10.1093/ejcts/ezw313
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125–e151. doi:10.1161/CIR.0000000000000665
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Bhatt DL, Cannon CP, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American Perspective: 2021 Update. Circulation. 2021;143(6):583–596. doi:10.1161/CIRCULATIONAHA.120.050438
   PubMed Web of Science ®Google Scholar
• Lopes RD, Hong H, Harskamp RE, et al. Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta-analysis of randomized controlled trials. JAMA Cardiol. 2019;4(8):747–755. doi:10.1001/jamacardio.2019.1880
   PubMed Web of Science ®Google Scholar
• Robinson AA, Trankle CR, Eubanks G, et al. Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi. JAMA Cardiol. 2020;5(6):685–692. doi:10.1001/jamacardio.2020.0652
   PubMed Web of Science ®Google Scholar
• Camaj A, Fuster V, Giustino G, et al. Left ventricular thrombus following acute myocardial infarction: JACC state-of-the-art review. J Am Coll Cardiol. 2022;79(10):1010–1022. doi:10.1016/j.jacc.2022.01.011
   PubMed Web of Science ®Google Scholar
• Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2023;44(38):3720–3826. doi:10.1093/eurheartj/ehad191
   PubMed Web of Science ®Google Scholar
• Li Y, Chen P, Wang X, et al. Methods for economic evaluations of novel oral anticoagulants in patients with atrial fibrillation: a systematic review. Appl Health Econ Health Pol. 2023;1:2.
   Google Scholar
• Sun KX, Cui B, Cao SS, et al. Cost-effectiveness analysis of direct oral anticoagulants versus vitamin k antagonists for venous thromboembolism in China. Front Pharmacol. 2021;12:716224. doi:10.3389/fphar.2021.716224
   PubMed Web of Science ®Google Scholar
• Zhou H, Nie X, Jiang M, Dong W. Cost-effectiveness of anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation in mainland China. J Clin Pharm Ther. 2022;47(4):523–530. doi:10.1111/jcpt.13575
   PubMed Web of Science ®Google Scholar
• Zhu Z, Wang Q, Sun Q, Lexchin J, Yang L. Improving access to medicines and beyond: the national volume-based procurement policy in China. BMJ Global Health. 2023;8(7):e011535. doi:10.1136/bmjgh-2022-011535
   PubMed Web of Science ®Google Scholar
• Yang Q, Lang X, Quan X, Gong Z, Liang Y, Mansour A. Different oral antithrombotic therapy for the treatment of ventricular thrombus: an observational study from 2010 to 2019. Int J Clin Pract. 2022;2022:7400860. doi:10.1155/2022/7400860
   PubMed Web of Science ®Google Scholar
• da Silva Ferreira H, Lima Lopes J, Augusto J, et al. Effect of direct oral anticoagulants versus vitamin K antagonists or warfarin in patients with left ventricular thrombus outcomes: a systematic review and meta-analysis. Revista Portuguesa De Cardiol. 2023;42(1):63–70. doi:10.1016/j.repc.2021.11.013
   Web of Science ®Google Scholar
• Yue X, Li Y, Wu J, Guo JJ. Current development and practice of pharmacoeconomic evaluation guidelines for universal health coverage in China. Value in Health Regional Issues. 2021;24:1–5. doi:10.1016/j.vhri.2020.07.580
   PubMedGoogle Scholar
• Falk Hvidberg M, Hernández Alava M. Catalogues of EQ-5D-3L health-related quality of life scores for 199 chronic conditions and health risks for use in the UK and the USA. PharmacoEconomics. 2023;41(10):1287–1388. doi:10.1007/s40273-023-01285-4
   PubMed Web of Science ®Google Scholar
• Liu R, Shi J, Yang B, et al. Charting a path forward: policy analysis of China’s evolved DRG-based hospital payment system. Int Health. 2017;9(5):317–324. doi:10.1093/inthealth/ihx030
   PubMed Web of Science ®Google Scholar
• Humbert M, Simonneau G, Pittrow D, et al. Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant. 2022;41(6):716–721. doi:10.1016/j.healun.2022.02.002
   PubMed Web of Science ®Google Scholar
• Alcalai R, Butnaru A, Moravsky G, et al. Apixaban vs. warfarin in patients with left ventricular thrombus: a prospective multicentre randomized clinical trial‡. Eur Heart J Cardiovasc Pharmacother. 2022;8(7):660–667. doi:10.1093/ehjcvp/pvab057
   PubMed Web of Science ®Google Scholar
• Shrestha DB, Dawadi S, Dhakal B, et al. Direct oral anticoagulants (DOAC) versus vitamin K antagonist in left ventricular thrombus: an updated meta-analysis. Health Sci Rep. 2023;6(11):e1736. doi:10.1002/hsr2.1736
   PubMedGoogle Scholar
• Hao Y, Zhao D, Liu J, et al. Performance of management strategies with class i recommendations among patients hospitalized with ST-segment elevation myocardial infarction in China. JAMA Cardiol. 2022;7(5):484–491. doi:10.1001/jamacardio.2022.0117
   PubMed Web of Science ®Google Scholar
• Huang L, Tan Y, Pan Y. Systematic review of efficacy of direct oral anticoagulants and vitamin K antagonists in left ventricular thrombus. ESC Heart Fail. 2022;9(5):3519–3532. doi:10.1002/ehf2.14084
   PubMed Web of Science ®Google Scholar
• Yang Q, Quan X, Zhang Y, et al. An exploratory study of effectiveness and safety of rivaroxaban in patients with left ventricular thrombus (R-DISSOLVE). J Thromb Thrombol. 2023;55(4):649–659. doi:10.1007/s11239-023-02790-1
   PubMed Web of Science ®Google Scholar
• He AJ. Scaling-up through piloting: dual-track provider payment reforms in China’s health system. Health Policy Plann. 2023;38(2):218–227. doi:10.1093/heapol/czac080
   PubMed Web of Science ®Google Scholar
• Yang Y, Hu R, Geng X, et al. The impact of National Centralised Drug Procurement policy on the use of policy-related original and generic drugs in China. Int J Health Plann Manag. 2022;37(3):1650–1662. doi:10.1002/hpm.3429
   PubMed Web of Science ®Google Scholar